Company intelligence / Profile preview

Achiko

Ownership: Private
Employees: ~10
Development stage: Other

Overview

Achiko develops rapid, affordable diagnostic solutions based on DNA aptamer technology. Its lead product, AptameX™, detects SARS-CoV‑2 and has been launched commercially in Indonesia and received a CE Mark for the EU. The company also offers Teman Sehat™, a digital health passport app. Clinical validation continues internationally, with plans to expand into additional infectious disease diagnostics using its core platform technologies.

Therapeutic areas: Infectious Diseases
Modalities: Device (diagnostic)DNA aptamer-based diagnostics
Industry: Molecular Diagnostics

Partnerships

Regenacellx.sl – partnership on Gumnuts technology development

Beyond the preview

Go deeper on Achiko.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Achiko.

Explore the full profile